An agreement signed last year under which Benitec granted the exclusive rights to use and sublicense its DNA-directed RNAi technology in areas outside human therapeutics to Promega might be coming apart, RNAi News has learned. According to court documents, Benitec has sued Promega for allegedly failing to meet its payment requirements under the companies’ arrangement.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.